AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28749253 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily vulvar Visnadine spray
Number of subjects: 38
Study 28749253 — intervention group
Group type: COMPARATOR
Intervention: On-demand vulvar Visnadine spray
Number of subjects: 38
Study 27566219 — intervention group
Group type: COMPARATOR
Intervention: Iron sulfate, 600mg orally daily for 4 weeks
Number of subjects: 100
Study 27566219 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron sulfate, 600mg orally daily for 4 weeks + rHuEPO, 4000 units subcutaneously, three times a week for 4 weeks
Number of subjects: 100
Study 25172965 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for patients ≥70 kg or 0.5 mg once daily for patients <70 kg)
Number of subjects: 360
Study 25172965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 25172965 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 360
Study 22448718 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous oxycodone (1 mg i.v. boluses, up to 5 mg cumulative dose)
Number of subjects: 15
Study 22448718 — intervention group
Group type: COMPARATOR
Intervention: Control group (newborns after uncomplicated deliveries with no systemic opioids)
Number of subjects: 15
Study 20722848 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based instruction
Number of subjects: 0
Study 20722848 — intervention group
Group type: COMPARATOR
Intervention: Paper-based instruction
Number of subjects: 0
Study 18443983 — intervention group
Group type: EXPERIMENTAL
Intervention: complete intervention
Number of subjects: 323
Study 18443983 — intervention group
Group type: EXPERIMENTAL
Intervention: partial intervention
Number of subjects: 323
Study 18443983 — intervention group
Group type: COMPARATOR
Intervention: non‐treatment
Number of subjects: 323
Study 16153270 — intervention group
Group type: EXPERIMENTAL
Intervention: Ischemic preconditioning (IP) by unstable angina
Number of subjects: 19
Study 16153270 — intervention group
Group type: COMPARATOR
Intervention: Control group (no angina)
Number of subjects: 19
Study 14565797 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol 2 mg
Number of subjects: 1
Study 14565797 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study 10378561 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiseptic-impregnated catheter (AIC)
Number of subjects: 101
Study 10378561 — intervention group
Group type: COMPARATOR
Intervention: Nonimpregnated catheter (NIC)
Number of subjects: 101
Study 9032584 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Number of subjects: 56
Study 9032584 — intervention group
Group type: COMPARATOR
Intervention: Four-week triple antimicrobial therapy (bismuth, tinidazole, amoxicillin)
Number of subjects: 56
Study 9032584 — intervention group
Group type: EXPERIMENTAL
Intervention: One-week triple antimicrobial therapy
Number of subjects: 56
Study 9032584 — intervention group
Group type: COMPARATOR
Intervention: Four-week triple antimicrobial therapy
Number of subjects: 56
Study 1648026 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous atrial natriuretic peptide (6 pmol/min/kg for 90 minutes)
Number of subjects: 6
Study 1648026 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 6
Study 6347755 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg three times a day)
Number of subjects: 31
Study 6347755 — intervention group
Group type: COMPARATOR
Intervention: Paracetamol (1 g three times a day)
Number of subjects: 31
Study 30758110 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable osteosynthesis
Number of subjects: 40
Study 30758110 — intervention group
Group type: COMPARATOR
Intervention: Titanium osteosynthesis
Number of subjects: 40
Study 27492145 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo ward care (KWC)
Number of subjects: 62
Study 27492145 — intervention group
Group type: COMPARATOR
Intervention: Intermediate intensive care (IIC)
Number of subjects: 62
Study 25377297 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary Continence Physiotherapy Programme (n=27)
Number of subjects: 55
Study 23261418 — intervention group
Group type: EXPERIMENTAL
Intervention: High access cost condition with an interruption lag
Number of subjects: 0
Study 23261418 — intervention group
Group type: COMPARATOR
Intervention: No lag control condition
Number of subjects: 0
Study 21689448 — intervention group
Group type: EXPERIMENTAL
Intervention: 100,000 IU vitamin D2
Number of subjects: 65
Study 21689448 — intervention group
Group type: EXPERIMENTAL
Intervention: 50,000 IU vitamin D2
Number of subjects: 65
Study 21689448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 20001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone (SPI)
Number of subjects: 64
Study 20001457 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretic (TCTZ)
Number of subjects: 64
Study 16758042 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (3 doses of 400 IU/kg per week for 6 weeks)
Number of subjects: 60
Study 16758042 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Number of subjects: 60
Study 16758042 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment aside from conventional medications)
Number of subjects: 60
Study 16758042 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 15252213 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA) at 2.0 mg/kg up to 80 mg
Number of subjects: 37
Study 15252213 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH) at 1 mg/kg up to 40 mg
Number of subjects: 37
Study 15252213 — intervention group
Group type: COMPARATOR
Intervention: Triamcinolone hexacetonide (TH)
Number of subjects: 37
Study 15252213 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 37
Study 11682374 — intervention group
Group type: COMPARATOR
Intervention: Routine medical information through an informative pamphlet (Group I)
Number of subjects: 60
Study 11682374 — intervention group
Group type: EXPERIMENTAL
Intervention: Extensive oral medical information and more personal attention by the surgeon (Group II)
Number of subjects: 60
Study 9782138 — intervention group
Group type: EXPERIMENTAL
Intervention: Goserelin depot treatment for 8 weeks before endometrial resection
Number of subjects: 63
Study 9782138 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgery in the early proliferative phase of the cycle
Number of subjects: 63
Study 8145906 — intervention group
Group type: EXPERIMENTAL
Intervention: rIFNA (9 million IU, intramuscularly every other day for 6 months)
Number of subjects: 20
Study 8145906 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intramuscularly every other day for 6 months)
Number of subjects: 20
Study 3136830 — intervention group
Group type: EXPERIMENTAL
Intervention: Buserelin and human menopausal gonadotrophin
Number of subjects: 405
Study 3136830 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate and human menopausal gonadotrophin
Number of subjects: 405
Study 31175711 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril + Amlodipine
Number of subjects: 30
Study 31175711 — intervention group
Group type: COMPARATOR
Intervention: Perindopril + Indapamide
Number of subjects: 30
Study 27705012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled sedation (PCS)
Number of subjects: 956
Study 27705012 — intervention group
Group type: COMPARATOR
Intervention: Anesthesiologist administered propofol sedation
Number of subjects: 956
Study 27705012 — intervention group
Group type: COMPARATOR
Intervention: All methods of sedation
Number of subjects: 956
Study 26246593 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Education Through Simulation‐Diabetes (PETS‐D)
Number of subjects: 191
Study 24059875 — intervention group
Group type: EXPERIMENTAL
Intervention: A‐SEMI (community-based intervention)
Number of subjects: 278
Study 24059875 — intervention group
Group type: COMPARATOR
Intervention: HPC (health promotion condition)
Number of subjects: 278
Study 22103045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 7 days
Number of subjects: 307
Study 22103045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 10 days
Number of subjects: 307
Study 22103045 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg bid, Clarithromycin 500 mg bid, Amoxycillin 1gr bid for 14 days
Number of subjects: 307
Study 19696643 — intervention group
Group type: EXPERIMENTAL
Intervention: Tri-iodothyronine (T3)
Number of subjects: 79
Study 19696643 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 79
Study 19696643 — intervention group
Group type: EXPERIMENTAL
Intervention: Both T3 and MP
Number of subjects: 79
Study 19696643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 16510816 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and screw fixation
Number of subjects: 41
Study 16510816 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary arthrodesis of the medial two or three rays
Number of subjects: 41
Study 12771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifetime cumulative tobacco consumption and alcohol consumption
Number of subjects: 105
Study 12771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Clear eyes
Number of subjects: 105
Study 12771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative sun exposure during outdoor work
Number of subjects: 105
Study 12771984 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin reaction to sun exposure (Fitzpatrick levels)
Number of subjects: 105
Study 10696955 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation (66 mg iron tablets)
Number of subjects: 206
Study 10696955 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 206
Study 9491846 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide: 200 mg x day x 5 days orally every 3 weeks
Number of subjects: 60
Study 9491846 — intervention group
Group type: COMPARATOR
Intervention: Fluorouracil: 500 mg x m2, Doxorubicin: 50 mg/m2, Cyclophosphamide: 500 mg/m2 intravenously every 3 weeks
Number of subjects: 60
Study 11767315 — intervention group
Group type: EXPERIMENTAL
Intervention: Ringer's lactate (2 litres over half an hour)
Number of subjects: 8
Study 11767315 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin (0.8 litre over half an hour)
Number of subjects: 8
Study 3735050 — intervention group
Group type: EXPERIMENTAL
Intervention: New Generation cup
Number of subjects: 123
Study 3735050 — intervention group
Group type: COMPARATOR
Intervention: BIRD's original vacuum extractor cup
Number of subjects: 123
Study 3735050 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 123
Study 28256100 — intervention group
Group type: EXPERIMENTAL
Intervention: UWIN questionnaire
Number of subjects: 294
Study 28256100 — intervention group
Group type: COMPARATOR
Intervention: AUASI questionnaire
Number of subjects: 294
Study 28390206 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Toothbrush (soft toothbrush with tapered-tip bristles)
Number of subjects: 71
Study 28390206 — intervention group
Group type: COMPARATOR
Intervention: ADA Toothbrush (ADA reference toothbrush)
Number of subjects: 71
Study 24468678 — intervention group
Group type: EXPERIMENTAL
Intervention: Phaseolin treated mice
Number of subjects: 0
Study 24468678 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 22490179 — intervention group
Group type: EXPERIMENTAL
Intervention: Active musical experience for 6 months
Number of subjects: 0
Study 22490179 — intervention group
Group type: COMPARATOR
Intervention: Passive exposure to music for 6 months
Number of subjects: 0
Study 20362709 — intervention group
Group type: EXPERIMENTAL
Intervention: NT‐proBNP guided care
Number of subjects: 151
Study 20362709 — intervention group
Group type: COMPARATOR
Intervention: Standard HF management
Number of subjects: 151
Study 19025304 — intervention group
Group type: EXPERIMENTAL
Intervention: Hp-seropositive university students' families
Number of subjects: 30
Study 19025304 — intervention group
Group type: COMPARATOR
Intervention: Hp-seronegative university students' families
Number of subjects: 30
Study 19025304 — intervention group
Group type: EXPERIMENTAL
Intervention: Families of Hp-positive students
Number of subjects: 30
Study 19025304 — intervention group
Group type: COMPARATOR
Intervention: Families of Hp-negative students
Number of subjects: 30
Study 16020262 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% timolol maleate ophthalmic gelling vehicle
Number of subjects: 0
Study 16020262 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate ophthalmic solution
Number of subjects: 0
Study 12823166 — intervention group
Group type: EXPERIMENTAL
Intervention: NET + WT
Number of subjects: 102
Study 12823166 — intervention group
Group type: COMPARATOR
Intervention: WT alone
Number of subjects: 102
Study 11284610 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 11284610 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 8646871 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate cream, 0.05%
Number of subjects: 120
Study 8646871 — intervention group
Group type: COMPARATOR
Intervention: Hydrocortisone-17-butyrate cream, 0.1%
Number of subjects: 120
Study 8646871 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 120
Study 8134276 — intervention group
Group type: EXPERIMENTAL
Intervention: CAD CAM (CAPOD) socket
Number of subjects: 22
Study 8134276 — intervention group
Group type: COMPARATOR
Intervention: Conventional socket
Number of subjects: 22
Study 3302925 — intervention group
Group type: EXPERIMENTAL
Intervention: Rimantadine for five days
Number of subjects: 91
Study 3302925 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen for five days
Number of subjects: 91
Study 29553289 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance and resistance training (training group, TG)
Number of subjects: 27
Study 29553289 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 27
Study 27583312 — intervention group
Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 374
Study 27583312 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin/Warfarin
Number of subjects: 374
Study 26577962 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative Pressure Wound Therapy (NPWT) using Vacuum Assisted Closure (VAC)
Number of subjects: 278
Study 26577962 — intervention group
Group type: COMPARATOR
Intervention: Advanced Moist Wound Therapy (AMWT)
Number of subjects: 278
Study 23890516 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin (10/20 and 10/40 mg)
Number of subjects: 1000
Study 23890516 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin (10, 20, 40 mg)
Number of subjects: 1000
Study 23890516 — intervention group
Group type: EXPERIMENTAL
Intervention: ezetimibe/simvastatin
Number of subjects: 1000
Study 23890516 — intervention group
Group type: COMPARATOR
Intervention: atorvastatin
Number of subjects: 1000
Study 21909448 — intervention group
Group type: EXPERIMENTAL
Intervention: DENV-1 infection
Number of subjects: 248
Study 21909448 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary dengue infection
Number of subjects: 248
Study 21909448 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary infection
Number of subjects: 248
Study 21909448 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary vs Secondary infections
Number of subjects: 248
Study 21909448 — intervention group
Group type: EXPERIMENTAL
Intervention: DHF
Number of subjects: 248
Study 18184117 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 (25, 50, or 75 mg/day)
Number of subjects: 1469
Study 18184117 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg/day
Number of subjects: 1469
Study 18184117 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 75 mg/day
Number of subjects: 1469
Study 18184117 — intervention group
Group type: COMPARATOR
Intervention: Esomeprazole 20 mg
Number of subjects: 1469
Study 18184117 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865 (all doses)
Number of subjects: 1469
Study 18184117 — intervention group
Group type: EXPERIMENTAL
Intervention: AZD0865
Number of subjects: 1469
Study 17009840 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation (250 mg, 10 ml)
Number of subjects: 24
Study 17009840 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation (Pactens) (250 mg, 10 ml)
Number of subjects: 24
Study 14648727 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal optimization
Number of subjects: 25
Study 14648727 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 25
Study 11082378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan patients (TCPC)
Number of subjects: 68
Study 11082378 — intervention group
Group type: EXPERIMENTAL
Intervention: Fontan patients (APC)
Number of subjects: 68
Study 11082378 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy volunteers (control)
Number of subjects: 68
Study 11082378 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 68
Study 8907209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet
Number of subjects: 0
Study 8907209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine
Number of subjects: 0
Study 8907209 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control mentioned)
Number of subjects: 0
Study 8907209 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and cholestyramine
Number of subjects: 0
Study 10303913 — intervention group
Group type: EXPERIMENTAL
Intervention: New treatment
Number of subjects: 0
Study 10303913 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 619945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with metoclopramide
Number of subjects: 10
Study 619945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with normal saline
Number of subjects: 10
Study 619945 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral propranolol (80 mg) with propantheline
Number of subjects: 10
Study 619945 — intervention group
Group type: COMPARATOR
Intervention: Oral propranolol (80 mg)
Number of subjects: 10
Study 31433921 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG plus medical therapy
Number of subjects: 601
Study 31433921 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 601
Study 31433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups (CABG and medical therapy, medical therapy alone)
Number of subjects: 601
Study 31433921 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial viability
Number of subjects: 601
Study 28167190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pectoralis minor muscle stretching by active scapular retraction
Number of subjects: 60
Study 28167190 — intervention group
Group type: COMPARATOR
Intervention: Control group (upright position)
Number of subjects: 60
Study 25978741 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 800
Study 25978741 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 800
Study 25978741 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 23053133 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine (CR, N = 9)
Number of subjects: 18
Study 23053133 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL, N = 9)
Number of subjects: 18
Study 22074851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-condition collaborative care intervention for depression and poorly controlled diabetes and/or risk factors for coronary heart disease over 12 months.
Number of subjects: 214
Study 22074851 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 214
Study 22074851 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-condition collaborative care intervention for disabilities in activities of daily living.
Number of subjects: 214
Study 19365567 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS02A vaccine
Number of subjects: 2022
Study 19365567 — intervention group
Group type: COMPARATOR
Intervention: Control vaccines
Number of subjects: 2022
Study 16436363 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice of S1 followed by S2 (experimental group)
Number of subjects: 30
Study 16436363 — intervention group
Group type: COMPARATOR
Intervention: Practice of S1 only (control group)
Number of subjects: 30
Study 16436363 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice of S2 after S1 (experimental group)
Number of subjects: 30
Study 15574629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone, 1 mg/kg per day for 12 days, then 0.5 mg/kg per day for 3 days
Number of subjects: 360
Study 15574629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 15574629 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone with indomethacin
Number of subjects: 360
Study 15574629 — intervention group
Group type: COMPARATOR
Intervention: Placebo with indomethacin
Number of subjects: 360
Study 11382656 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified candies (30 g/week for 12 weeks, containing 1 mg elemental Fe/g)
Number of subjects: 117
Study 11382656 — intervention group
Group type: COMPARATOR
Intervention: Placebo candies (30 g/week for 12 weeks)
Number of subjects: 117
Study 11382656 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron-fortified candies
Number of subjects: 117
Study 11382656 — intervention group
Group type: COMPARATOR
Intervention: Placebo candies
Number of subjects: 117
Study 9458496 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined reporting of increased serum calcium and results from diagnostic discriminating calculations in group A
Number of subjects: 87
Study 9458496 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting of serum calcium only if requested in group B
Number of subjects: 87
Study 7924775 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein diet (LPD) - 0.5 g.kg‐1.day‐1 of proteins, 7% calories as protein, 33% as fat, and 60% as carbohydrates
Number of subjects: 15